A single and multiple ascending dose study to evaluate the safety, tolerability and PK of ALKS 2680 in healthy subjects and subjects with hypersomnia
Latest Information Update: 30 May 2025
At a glance
- Drugs ALKS 2680 (Primary)
- Indications Idiopathic hypersomnia; Narcolepsy
- Focus Adverse reactions; First in man; Proof of concept
- Sponsors Alkermes
Most Recent Events
- 29 May 2025 According to an Alkermes plc media release, the company will present data from this trial at the SLEEP 2025, the 38th annual meeting of the Associated Professional Sleep Societies (APSS), taking place June 8-11, 2025 in Seattle.
- 07 Nov 2024 According to an Alkermes plc media release, the company presented data from this study at 37th Annual Psych Congress (Psych Congress), which took place Oct. 29-Nov. 2, 2024 in Boston
- 23 Sep 2024 According to an Alkermes plc media release, company plans to present clinical data from this study at the European Sleep Research Society's (ESRS) 27th Congress, Sleep Europe 2024, taking place Sept. 24-27, 2024 in Seville, Spain.